Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in Human Plasma.
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC with a high drug-antibody ratio (DAR). Although the drug showed promise in Phase I clinical development, earlier this year Mersana and Takeda agreed to prioritize resources to focus on the advancement of another ADC, XMT-1536, a first-in-class ADC candidate targeting NaPi2b, ending the co-development collaboration for XMT-1522.
Thank you for registering!
You may now view the resource below.
Liquid biopsy is a sampling method for biomarker analysis that minimizes invasiveness, allows routine sampling, and is associated with circulating cell-free DNA. In this webinar, we talk about the benefits and challenges of sequencing cell-free DNA.
Pregabalin, (S)-3-(aminomethyl)-5-methylhexanoic acid, is an analogue of the neurotransmitter gamma amino butyric acid (GABA). It is used for the treatment of peripheral and central neuropathic pain in adults and as an adjunctive therapy for refractory partial seizures. Pregabalin binds potently to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in the central nervous system and its binding at this site reduces calcium influx at the nerve terminal, leading to the release of several neurotransmitters, such as glutamate and noradrenalin. The aim of this study is to develop a sensitive, specific, robust and rapid LC-MS/MS method: Use simple extraction procedure; With no interference from matrix; With short run time.